Palatin Technologies (PTN) Q4 2024 earnings summary

Executive summary

• Completed sale of Vyleesi rights for HSDD to Cosette Pharmaceuticals for up to $171 million, with $12 million upfront and up to $159 million in milestones; retained rights for other indications.

• Fiscal 2024 marked significant progress in pipeline programs, especially in ocular, obesity, sexual dysfunction, ulcerative colitis, and diabetic nephropathy therapeutics, with multiple pivotal studies underway and topline results expected in 2024–2025.

• Raised $21 million in gross proceeds from financings during fiscal 2024.

Financial highlights

• Fiscal year 2024 Vyleesi gross product sales were $8.9 million, net product revenue $4.5 million, down from $12.5 million and $4.9 million, respectively, year-over-year.

• No product sales recorded in Q4 2024 due to asset sale; Q4 2023 gross product sales were $4.1 million, net revenue $1.8 million.

• Total operating expenses for fiscal 2024 were $27 million, down from $37.3 million in 2023.

• Net loss for fiscal 2024 was $29.7 million, compared to $24 million in 2023; Q4 2024 net loss was $8.6 million, compared to $9.8 million in Q4 2023.

• Cash and cash equivalents as of June 30, 2024, were $9.5 million.

Outlook and guidance

• PL-9643 phase 3 program for dry eye disease to be completed in 2025, with NDA filing anticipated in H1 2026; phase 3 studies to begin enrollment in Q1 2025, topline results expected Q4 2025.

• Phase 2 obesity study (bremelanotide + tirzepatide) to complete enrollment early Q4 2024, with data expected Q1 2025.

• Next-gen MC4R agonist lead selection in Q1 2025, IND and first-in-human studies in H2 2025.

• Male sexual dysfunction program to start pharmacokinetic study in Q1 2025, phase 2/3 recruitment in H2 2025.

• PL-8177 ulcerative colitis phase 2 interim data expected Q4 2024, topline results Q1 2025; diabetic nephropathy phase 2 topline results expected Q4 2024.